Ozempic is a registered trademark of Novo Nordisk A/S. It is a prescription medicine containing semaglutide. Its FDA-approved uses apply to certain adults with type 2 diabetes, as described in the official labeling. A licensed clinician decides whether it is appropriate for a patient.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Important safety information
Ozempic carries a boxed warning about the risk of thyroid C-cell tumors. Semaglutide caused thyroid C-cell tumors in rodents. It is not known whether it causes these tumors, including medullary thyroid carcinoma, in people.
Ozempic must not be used by anyone with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. It is also contraindicated in people who have had a serious hypersensitivity reaction to semaglutide or its ingredients.
Serious risks described in the labeling include inflammation of the pancreas, diabetic retinopathy complications, low blood sugar when used with insulin or certain diabetes medicines, kidney injury related to dehydration, serious allergic reactions, gallbladder problems, and aspiration during anesthesia or deep sedation. Common side effects include nausea, vomiting, diarrhea, stomach pain, and constipation.
Read the complete official Ozempic Prescribing Information and Medication Guide, including the boxed warning, indications, limitations, contraindications, warnings, and adverse reactions.
The FDA-approved uses
According to the FDA-approved prescribing information, Ozempic is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
The labeling also includes uses for reducing certain major cardiovascular risks in adults with type 2 diabetes who have established cardiovascular disease, and for reducing the risk of certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. The exact populations and outcomes are defined in the official prescribing information.
Those details matter. An approved use is not a recommendation for every person who has diabetes, heart disease, or kidney disease. A clinician must consider the full medical history, current medicines, contraindications, and treatment goals.
Ozempic is not indicated for type 1 diabetes. It is also not a substitute for insulin. The label notes that it has not been studied in people with a history of pancreatitis, so a clinician needs to review that history carefully.
Is Ozempic approved for weight loss?
Ozempic is not FDA-approved as a weight-loss medicine. Changes in appetite or body weight can occur during treatment, but that does not change its labeled uses.
This distinction is easy to miss because semaglutide is the active ingredient in more than one prescription product. Products with the same active ingredient can have different FDA-approved uses, doses, presentations, and instructions. They should not be treated as interchangeable.
A clinician may prescribe an approved medicine for an unapproved use when medically appropriate. This is often called off-label prescribing. An online article cannot determine whether that is suitable for a particular person, and insurance may apply different rules to a prescription outside the FDA-approved use.
How it works
Semaglutide belongs to a class called GLP-1 receptor agonists. The prescribing information explains that it helps the pancreas release insulin when blood sugar is elevated, reduces the release of glucagon, and slows stomach emptying.
Those effects can help improve blood sugar control. They can also interact with other parts of a treatment plan. For example, the risk of low blood sugar can rise when Ozempic is used with insulin or an insulin secretagogue such as a sulfonylurea. A clinician may need to review doses and monitoring.
Ozempic is given as an injection under the skin once weekly, according to the label. The dose starts low and may be increased on the labeled schedule. Patients should follow the instructions supplied with their prescription and should not change a dose or schedule based on general information online.
What a clinical evaluation should cover
A clinician will review more than a diagnosis. Relevant questions can include personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, diabetic eye disease, kidney problems, gallbladder disease, severe stomach symptoms, allergies, pregnancy plans, and upcoming procedures involving anesthesia or deep sedation.
The clinician also needs a complete medication list. That includes insulin, sulfonylureas, and oral medicines whose timing may matter because Ozempic delays stomach emptying.
Follow-up matters after a prescription is issued. Persistent severe stomach pain, symptoms of a serious allergic reaction, changes in vision, dehydration, or signs of low blood sugar need prompt clinical attention as directed in the Medication Guide. Patients should tell medical teams about their use before planned procedures.
Access and insurance are separate questions
Clinical eligibility does not ensure insurance coverage. A plan may review the diagnosis, labeled use, formulary, prior authorization criteria, and pharmacy network. Approval and payment are determined by the plan.
Body Good may offer coverage support, such as a benefit check and help with plan-requested paperwork. That is assistance with the process. It does not mean coverage is obtained, arranged, secured, or guaranteed.
Body Good's prices are service fees for the program described during intake. They are not the price of medication, and medication cost is separate and not included. Service fees are not a quote for any individual. Eligibility is determined by a clinician.
This website is an informational and pricing overview. It takes no payment, collects no protected health information, and runs no intake form. Intake and checkout take place on joinbodygood.com.
Frequently asked questions
Is Ozempic insulin?
No. Ozempic contains semaglutide, a GLP-1 receptor agonist. It is not insulin and is not a substitute for insulin.
Is Ozempic approved for weight loss?
No. Its FDA-approved uses concern certain adults with type 2 diabetes. A clinician can explain which treatment options have approved weight-management indications.
Who decides whether Ozempic is appropriate?
A licensed clinician makes that decision after reviewing medical history, medicines, risks, and treatment goals. Begin the secure intake to provide information for clinical review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.